Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib.

Kyoichi Kaira Hisao ImaiAtsuto MouriKosuke HashimotoYu MiuraAyako ShionoOu YamaguchiKunihiko KobayashiTomonori KawasakiMasanori YasudaHiroshi Kagamu

Published in: Thoracic cancer (2023)

VEGFR2 and VEGF-C are highly expressed in EGFR-mutant NSCLC cells. Increased expression of VEGFR2 was identified as a significant prognostic factor in patients with EGFR del19 mutation who received osimertinib, whereas co-high expression of VEGFR2 and VEGF-C was a significant predictor for those with EGFR L858R mutation.

Keyphrases

small cell lung cancer
vascular endothelial growth factor
epidermal growth factor receptor
advanced non small cell lung cancer
prognostic factors
endothelial cells
poor prognosis
brain metastases
tyrosine kinase
induced apoptosis
cell cycle arrest
cell death
signaling pathway
endoplasmic reticulum stress